

Table S4. Summary of Edema Severity Over Time – Safety Population

Visit Category	Placebo (N = 71) n (%)	MSDC-0160 50 mg (N = 71) n (%)	MSDC-0160 100 mg (N = 71) n (%)	MSDC-0160 150 mg (N = 70) n (%)	Pioglitazone 45 mg (N = 71) n (%)	Total (N = 354) n (%)
Baseline	N' = 71	N' = 70	N' = 71	N' = 70	N' = 71	N' = 353
Absent	63 (88.7)	62 (88.6)	62 (87.3)	66 (94.3)	65 (91.5)	318 (90.1)
1+	6 (8.5)	7 (10.0)	6 (8.5)	3 (4.3)	5 (7.0)	27 (7.6)
2+	2 (2.8)	1 (1.4)	1 (1.4)	0 (0.0)	0 (0.0)	4 (1.1)
3+	0 (0.0)	0 (0.0)	1 (1.4)	1 (1.4)	1 (1.4)	3 (0.8)
4+	0 (0.0)	0 (0.0)	1 (1.4)	0 (0.0)	0 (0.0)	1 (0.3)
Week 4	N' = 62	N' = 66	N' = 66	N' = 69	N' = 71	N' = 334
Absent	56 (90.3)	61 (92.4)	60 (90.9)	65 (94.2)	66 (93.0)	308 (92.2)
1+	5 (8.1)	5 (7.6)	3 (4.5)	3 (4.3)	4 (5.6)	20 (6.0)
2+	1 (1.6)	0 (0.0)	2 (3.0)	0 (0.0)	0 (0.0)	3 (0.9)
3+	0 (0.0)	0 (0.0)	1 (1.5)	1 (1.4)	1 (1.4)	3 (0.9)
4+	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Week 12	N' = 56	N' = 60	N' = 62	N' = 59	N' = 64	N' = 301
Absent	51 (91.1)	57 (95.0)	57 (91.9)	56 (94.9)	59 (92.2)	280 (93.0)
1+	4 (7.1)	3 (5.0)	2 (3.2)	1 (1.7)	4 (6.3)	14 (4.7)
2+	1 (1.8)	0 (0.0)	2 (3.2)	1 (1.7)	0 (0.0)	4 (1.3)
3+	0 (0.0)	0 (0.0)	1 (1.6)	1 (1.7)	1 (1.6)	3 (1.0)
4+	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

N' is the number of patients who had an assessment of edema at the specified visit.
 Baseline was defined as the measurement at Visit 2. If the Visit 2 measurement was missing, the last valid measurement prior to the first dose of randomized double-blind study medication was used.